# HHS Funds Psychotropic Treatment Research

On November 12, 2026, HHS announced up to $4.9 million over five years in ARPA-H performer awards to build regulatory, manufacturing, and clinical-data foundations for ibogaine research, plus a separate $20 million NIMH funding opportunity for a research network studying rapid-acting psychotropic treatments. The ARPA-H work supports preparation for future research, including domestic manufacturing and public release of findings; it does not fund patient treatment, human-subject research, or authorize clinical trials. NIMH expects to announce awardees in summer 2027, but the announcement provides no application deadline or solicitation number.

- Research-network and clinical-research organizations may find the NIMH opportunity relevant; the source provides an expected award announcement timeframe but no application deadline.
- The ARPA-H awards focus on regulatory and manufacturing groundwork, clinical data, safety, and preparation for possible future trials. These awards should not be treated as authorization to conduct clinical trials.
- Contractors and research institutions with relevant capabilities can assess whether their work aligns with the stated focus on domestic manufacturing, safety, and public release of findings.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding, Regulatory Compliance
**Published:** November 12, 2026

### Government Entities
- U.S. Department of Health and Human Services (HHS)
- Advanced Research Projects Agency for Health (ARPA-H)
- National Institute of Mental Health (NIMH)
- U.S. Food and Drug Administration (FDA)
- U.S. Department of Veterans Affairs (VA)

### Vendors
- Mark Cuban Cost Plus Drug Company, PBC (awardee)
- Beond, Inc. (awardee)

### Key Quotes
> Reports of successful ibogaine treatments are too promising to ignore. We owe it to our heroes and every person struggling to ask the bold questions and deliver results in years, not decades.
> — Al Bugazia, M.D., Senior Advisor for Special Projects at ARPA-H

> Veterans deserve effective treatments and clear answers about the benefits and risks of those treatments.
> — Doug Collins, VA Secretary

> We will pursue the evidence, confront the risks and put affordability at the center of this work.
> — Robert F. Kennedy, Jr., HHS Secretary

### Sources
- [HHS Announces ARPA-H Awards to Advance Ibogaine Development for PTSD & New $20 Million Funding Opportunity to Advance Rapid-acting Psychotropics | HHS.gov](https://www.hhs.gov/press-room/hhs-advances-ibogaine-ptsd-research-rapid-acting-mental-health-treatments.html) - HHS